Berberine modulates insulin signaling transduction in insulin-resistant cells

Liu, Lizhong; Cheung, Stanley C.K.; Lan, Linda; Ho, Stanley; Xu, Hong‐Xi; Chan, Juliana C.N.; Tong, Peter C.Y.

doi:10.1016/j.mce.2009.12.027

Cited by 64 publications

(46 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HPLC analysis revealed that both catechin and epicatechin were present in EeSs (Figure 1(c)). Therefore, the antidiabetic effect of EeSs is mediated at least in part by the activation of AKT and/or AMPK; this finding is supported by the results of a previous study [39]. …”

Section: Discussionsupporting

confidence: 84%

Spatholobus suberectus Exhibits Antidiabetic Activity In Vitro and In Vivo through Activation of AKT‐AMPK Pathway

Zhao

Alam

Lee

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Glucose deposition in peripheral tissue is an important parameter for the treatment of type 2 diabetes mellitus. The aim of this study was to investigate the effects of Spatholobus suberectus (Ss) on glucose disposal in skeletal muscle cells and additionally explore its in vivo antidiabetic potential. Treatment of ethanolic extract of S. suberectus (EeSs) significantly enhanced the glucose uptake, mediated through the enhanced expression of GLUT4 in skeletal muscle via the stimulation of AKT and AMPK pathways in C2C12 cells. Moreover, EeSs have potential inhibitory action on α-glucosidase activity and significantly lowered the postprandial blood glucose levels in STZ-induced diabetic mice, associated with increased expression of GLUT4 and AKT and/or AMPK-mediated signaling cascade in skeletal muscle. Furthermore, administration of EeSs significantly boosted up the antioxidant enzyme expression and also mitigated the gluconeogenesis enzyme such as PEPCK and G-6-Pase enzyme expression in liver tissue of STZ-induced diabetic mice model. Collectively, these findings suggest that EeSs have a high potentiality to mitigate diabetic symptoms through stimulating glucose uptake in peripheral tissue via the activation of AKT and AMPK signaling cascade and augmenting antioxidant potentiality as well as blocking the gluconeogenesis process in diabetic mice.

show abstract

Section: Discussionsupporting

confidence: 84%

Spatholobus suberectus Exhibits Antidiabetic Activity In Vitro and In Vivo through Activation of AKT‐AMPK Pathway

Zhao

Alam

Lee

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Our present results showed that BER significantly inhibited the two key enzymes PEPCK and G6Pase protein level and RNA expression in diabetic rats, while the inhibitory effect of the combination of BER with sodium caprate was more noticeable. The results illustrate that BER not only promotes glucose uptake (Kim et al, 2007; Liu et al, 2010a,b), but also inhibits glucose production in liver.…”

Section: Discussionmentioning

confidence: 84%

“…Liu et al reported that BER exhibited synergistic effect on insulin-induced glucose uptake and GLUT4 translocation in insulin- resistant state accompanied by enhancement in insulin-induced PKCzeta and PKB activity. The key mechanism was related to the inhibition of mTOR and activation of AMPK by BER, which attenuated serine-phosphorylation of IRS-1 (Liu et al, 2010a,b). BER also stimulated glucose uptake and increased the expression of GLUT1 via AMPK in 3T3-L1 adipocytes (Kim et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis

Zhang

et al. 2012

Molecular and Cellular Endocrinology

View full text Add to dashboard Cite

Berberine (BER), a natural product and active ingredient of genera Berberis and Coptis, has been demonstrated to possess anti-diabetic activities. However, the poor bioavailability of this agent greatly limits its clinical application. In our previous study, we demonstrated that co-administration of sodium caprate, an absorption enhancer, with BER could significantly increase the bioavailability of BER without any serious mucosal damage. Here, we investigated the effects of BER on AMP-activated protein kinase (AMPK)/gluconeogenesis pathway and the effects of sodium caprate on hypoglycemic action of BER. The ability of BER co-administered with sodium caprate to reduce insulin resistance was investigated in diabetic rat model induced by high-fat diet and low dose STZ. Western blot was performed to evaluate effects of BER on AMPK signaling proteins involved in hepatic gluconeogenesis in diabetic rat and HepG2 hepatocytes. BER reduced body weight and caused a significant improvement in glucose tolerance without altering food intake in diabetic rats. Similarly, BER reduced plasma triglycerides and improved insulin action in diabetic rats. BER down-regulated the elevated expressions of gluconeogenesis key enzymes PEPCK and G6Pase, inhibited the translocation of TORC2 from cytoplasm to nucleus and increased AMPK activity in liver tissues. The effect of BER was higher when co-administered with sodium caprate. BER treatment resulted in reduced glucose production in HepG2 hepatocytes. BER increased AMPK activity, reduced the expression of PEPCK, and the nuclear transcription factors PGC-1, HNF-4α and FOXO1. The effect of BER on gluconeogenesis could be partly blocked by AMPK inhibitor, Compound C. BER could suppress hepatic gluconeogenesis in rat model of diabetes at least in part via stimulation of AMPK activity and this action of BER is augmented by sodium caprate.

show abstract

“…In obese db/db and ob/ob mice, berberine treatment improved lipid dysregulation and fatty liver, and changed the expression of genes involved in lipid metabolism [91]. In studies carried out on insulin-resistant rat skeletal muscle cells, the effects of berberine were indicative of an action on the insulin signaling pathway, leading to increased glucose uptake in insulinresistant cells [92]. These effects were possibly mediated by a reversal of the methylation state of promoters of key genes involved in lipid and glucose metabolism [93].…”

Section: Potential Development Issuesmentioning

confidence: 99%

Treatment of non-alcoholic fatty liver disease with focus on emerging drugs

Marchesini¹,

Moscatiello²,

Agostini³

et al. 2011

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

Weight loss remains the cornerstone of treatment of hepatic steatosis, but difficult to pursue. A pragmatic approach relies on generic recommendations for weight loss and physical activity in the whole population and limiting interventions to subject at risk of disease progression, but the type of preferred treatment remains a matter of debate. The large number and mechanistic diversity of drugs that have so far been investigated bear testimony to the lack of a specific, effective agent. Insulin resistance remains the pivotal alteration responsible for liver disease and its progression and insulin sensitizers are regarded as the treatment of choice. Several ongoing studies are testing the effectiveness of new approaches on histological outcomes and new metabolic pathways are under scrutiny.

show abstract

Berberine modulates insulin signaling transduction in insulin-resistant cells

Cited by 64 publications

References 38 publications

Spatholobus suberectus Exhibits Antidiabetic Activity In Vitro and In Vivo through Activation of AKT‐AMPK Pathway

Spatholobus suberectus Exhibits Antidiabetic Activity In Vitro and In Vivo through Activation of AKT‐AMPK Pathway

Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis

Treatment of non-alcoholic fatty liver disease with focus on emerging drugs

Contact Info

Product

Resources

About